Stock Scorecard



Stock Summary for Gilead Sciences Inc (GILD) - $111.25 as of 7/1/2025 7:28:06 AM EST

Total Score

12 out of 30

Safety Score

72 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for GILD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GILD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GILD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GILD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GILD (72 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 6
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 7
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for GILD

Should You Invest in the VanEck Biotech ETF ( BBH ) ? 6/30/2025 10:20:00 AM
Gilead Sciences ( GILD ) Beats Stock Market Upswing: What Investors Need to Know 6/27/2025 9:50:00 PM
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy - Abbott Laboratories ( NYSE:ABT ) , Amazon.com ( NASDAQ:AMZN ) 6/27/2025 3:39:00 PM
Gilead Sciences, Inc. ( GILD ) Is a Trending Stock: Facts to Know Before Betting on It 6/27/2025 1:00:00 PM
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update 6/26/2025 12:40:00 PM
Gilead Sciences ( GILD ) Stock Moves -1.18%: What You Should Know 6/25/2025 10:00:00 PM
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences ( NASDAQ:GILD ) , Sanofi ( NASDAQ:SNY ) 6/25/2025 1:23:00 PM
Aisera Named to Inc.'s 2025 Best Workplaces List 6/25/2025 1:00:00 PM
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B 6/25/2025 12:00:00 PM
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch 6/24/2025 4:15:00 PM

Financial Details for GILD

Company Overview

Ticker GILD
Company Name Gilead Sciences Inc
Country USA
Description Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 111.25
Price 4 Years Ago 63.38
Last Day Price Updated 7/1/2025 7:28:06 AM EST
Last Day Volume 6,599,136
Average Daily Volume 8,676,158
52-Week High 118.28
52-Week Low 63.95
Last Price to 52 Week Low 73.96%

Valuation Measures

Trailing PE 23.25
Industry PE 60.05
Sector PE 40.73
5-Year Average PE 22.32
Free Cash Flow Ratio 17.46
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 1.37
Total Cash Per Share 6.37
Book Value Per Share Most Recent Quarter 15.39
Price to Book Ratio 7.18
Industry Price to Book Ratio 18.77
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 4.79
Industry Price to Sales Ratio Twelve Trailing Months 48.41
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings 15
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 1,243,930,000
Market Capitalization 138,387,212,500
Institutional Ownership 89.72%

Dividends

Ex-Dividend Date 6/13/2025
Previous Dividend Amount 0.7900
Current Dividend Amount 0.7900
Total Years Dividend Increasing Dividend Contender - Increasing for 10 Years
Trailing Annual Dividend Rate 3.12
Trailing Annual Dividend Yield 2.90%
Forward Annual Dividend Rate 3.16
Forward Annual Dividend Yield 2.94%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 3.38%
5-Year Average Dividend Yield 3.87%
1-Year Dividend Growth Rate Percentage 2.60%
3-Year Dividend Growth Rate Percentage 1.29%
5-Year Dividend Growth Rate Percentage 2.71%
All-Time Dividend Growth Rate Percentage 6.65%
Dividend Payout Ratio 65.55%

Income Statement

Quarterly Earnings Growth YOY 24.80%
Annual Earnings Growth -91.53%
Reported EPS 12 Trailing Months 4.76
Reported EPS Past Year 1.81
Reported EPS Prior Year 4.61
Net Income Twelve Trailing Months 5,965,000,000
Net Income Past Year 480,000,000
Net Income Prior Year 5,665,000,000
Quarterly Revenue Growth YOY -0.30%
5-Year Revenue Growth 5.08%
Operating Margin Twelve Trailing Months 38.50%

Balance Sheet

Total Cash Most Recent Quarter 7,926,000,000
Total Cash Past Year 9,991,000,000
Total Cash Prior Year 6,085,000,000
Net Cash Position Most Recent Quarter -14,220,000,000
Net Cash Position Past Year -14,905,000,000
Long Term Debt Past Year 24,896,000,000
Long Term Debt Prior Year 23,189,000,000
Total Debt Most Recent Quarter 22,146,000,000
Equity to Debt Ratio Past Year 0.44
Equity to Debt Ratio Most Recent Quarter 0.46
Total Stockholder Equity Past Year 19,330,000,000
Total Stockholder Equity Prior Year 22,833,000,000
Total Stockholder Equity Most Recent Quarter 19,162,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 9,844,000,000
Free Cash Flow Per Share Twelve Trailing Months 7.91
Free Cash Flow Past Year 10,305,000,000
Free Cash Flow Prior Year 7,421,000,000

Options

Put/Call Ratio 0.98
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.62
MACD Signal 0.89
20-Day Bollinger Lower Band 98.37
20-Day Bollinger Middle Band 107.45
20-Day Bollinger Upper Band 116.52
Beta 0.31
RSI 58.21
50-Day SMA 93.45
150-Day SMA 78.36
200-Day SMA 73.00

System

Modified 7/1/2025 12:58:09 AM EST